Author: Vikas Kumar
07 September 2021
Endobronchial Valve System Market is expected to exceed the market valuation of more than US$ XX million by 2027 expanding at a reasonable CAGR of around XX% during the forecast period (2021-2027). Chronic Obstructive Pulmonary Disease (COPD) affects 251 million people worldwide and causes 5% of global deaths. COPD can cause a high-cost burden across many regions worldwide. The endobronchial valves placement procedure costs US$ 15,000 in 2018 including the 3-night stay. This is way lower than the cost of COPD drugs which can cost from US$ 30,000 to US$ 50,000. Furthermore, lung reduction surgeries cost US$ 50,000 and lung transplants cost US$ US$1 million. Endobronchial valves treatment is the most cost effective among all and is also efficient and effective. COPD is a progressive and heterogeneous disease involving a spectrum of pathophysiological mechanisms including destruction of alveoli and lung parenchyma (emphysema) and small airway inflammation (obstructive bronchiolitis). Endobronchial Valve placement can be a cost-effective treatment for this chronic disorder.
For a detailed analysis of the Endobronchial Valve System Market browse through – https://univdatos.com/report/endobronchial-valve-system-market
The endobronchial valves market is still in its nascent stage; however, the market is expected to grow significantly in the coming years with the rising awareness of the bronchoscopic lung volume reduction procedures. Additionally, the rise in tobacco smoking is increasing the cases of lung disorders and causing growth in the market. Furthermore, rising COPD lung disorder and the geriatric population are also key factors to the increase in the endobronchial valves market. According to Healthline, 65 million people will have COPD around the world in the next 50 years. 4.6% of adults had COPD, emphysema, or chronic bronchitis in 2019 in the US alone. The endobronchial valve market is currently highly consolidated, with only key players holding a significant share. Pulmonx Corporation (Zephyr) and Spiration Inc. are the keys investing bodies in the development and introduction of new endobronchial valve products. In 2018, the U.S. FDA approved the Zephyr Valve, which is the first minimally invasive device for treating patients with severe emphysema.
For a detailed analysis of the market drivers in Endobronchial Valve System Market browse through – https://univdatos.com/report/endobronchial-valve-system-market
COPD patients have worse outcomes of Covid-19 according to a study conducted in China. An analysis of 1590 patients in China with Covid-19 showed that 62.5% of the severe cases had a history of COPD compared to only 15.3% of non-severe cases. Furthermore, 25% of the deaths were of COPD patients as compared to 2.8% survivors. Additionally, 15.7% of the COPD patients in a Chinese multicenter were critically ill and only 2.3% were moderately ill. This evidence is also confirmed by other similar studies. The recent uprise of the covid pandemic has made COPD patients vulnerable to the disease. This may increase the growth of endobronchial valves market as people are becoming more aware of the implications of COPD and the need to get treated. Even though elective surgeries have deteriorated in most countries because of the lockdown, important life saving EBV surgeries are still being performed and their numbers are affected by the covid cases.
For a detailed analysis of the Product in the Endobronchial Valve System Market browse through – https://univdatos.com/report/endobronchial-valve-system-market
Based on product, the market is bifurcated into Duckbill and Umbrella-shaped Endobronchial Valves. Amongst product, the Duckbill-shaped Endobronchial Valves segment was valued at US$ XX million in 2020 and is likely to reach US$ XX million by 2027 growing at a CAGR of XX% from 2021-2027. FDA approved two valves in 2018, the Zephyr EBV (Pulmonx) and the Spiration Valve System (Olympus) (IBV). The Zephyr EBV is a duckbill shaped silicone valve in a self-expanding nitinol (nickel titanium alloy) stent.
Based on end-user the endobronchial valves market is segmented into Hospitals, Clinical Research Centers, Ambulatory Surgery Centers and Others. Amongst end-user, hospital segment accounted for a market valuation of US$ XX million in 2020 and is expected to reach US$ XX million by the year 2027, at a CAGR of XX% over the analyzed period. The placement procedures are performed by a pulmonologist at the hospital. They use a flexible tube to place the valve in the airways into the disease’s parts of the lung. The procedures provide benefit with relatively low risks.
Request for Sample of the report browse through – https://univdatos.com/request_form/form/427
Additionally, the report provides detailed initiatives that are being taken in the field of Endobronchial Valve System, globally. The report provide a detailed analysis of regions including North America (the U.S, Canada, and Rest of North America), Europe (Germany, France, Spain, Italy, UK, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), and the Rest of the World. North America dominated the market in 2020, with XX% share. Pulmonx Corporation (Zephyr), Spiration Inc., MedLung, Novatech, and Olympus Corporation are some of the prominent players operating in the global Endobronchial Valve System market. Several M&As along with partnerships have been undertaken by these players to make Endobronchial Valve Systems as cost-effective and as widely available as possible.
Endobronchial Valve System Market Segmentation
Market Insight, by Product
Market Insight, by End-User
Market Insight, by Region
Top Company Profiles
Get a call back
